CONSOLIDATED FINANCIAL REPORT [IFRS]
for the Three-Month Period Ended June 30, 2026

August 3, 2026
Eisai Co., Ltd.

Stock exchange listing: Tokyo Stock Exchange (TSE)
TSE Code: 4523
URL: https://www.eisai.com

Representative: Haruo Naito, Representative Corporate Officer & CEO
Contact: Teruyuki Masaka, Vice President, Corporate Communications
Telephone: +81-3-3817-5120
Expected date of dividend payment commencement: —
Preparation of supplementary explanatory material: Yes
Financial results briefing held: Yes

(Figures are rounded to the nearest million yen)

1. Consolidated Financial Results for the Three-Month Period Ended June 30, 2026

(1) Consolidated Operating Results

(Percentage figures show year on year change)

	Revenue		Operating profit		Profit before income taxes		Profit for the period		Profit for the period attributable to owners of the parent		Comprehensive income for the period	
	(¥ million)	(%)	(¥ million)	(%)	(¥ million)	(%)	(¥ million)	(%)	(¥ million)	(%)	(¥ million)	(%)
Three-month period ended June 30, 2026	234,330	15.6	24,728	19.2	25,283	12.8	19,151	24.9	18,242	26.0	31,177	181.7
Three-month period ended June 30, 2025	202,651	7.2	20,744	54.7	22,404	40.3	15,337	33.2	14,474	36.8	11,067	-79.0

	Earnings per share attributable to owners of the parent (basic)	Earnings per share attributable to owners of the parent (diluted)
	(¥)	(¥)
Three-month period ended June 30, 2026	64.71	—
Three-month period ended June 30, 2025	51.35	—

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent	Equity per share attributable to owners of the parent
	(¥ million)	(¥ million)	(¥ million)	(%)	(¥)
As of June 30, 2026	1,558,091	933,169	906,564	58.2	3,216.02
As of March 31, 2026	1,449,113	925,124	898,992	62.0	3,189.15

2. Dividends

	Annual dividend per share				
	End of Q1	End of Q2	End of Q3	End of FY	Total
	(¥)	(¥)	(¥)	(¥)	(¥)
FY 2025	—	80.00	—	80.00	160.00
FY 2026	—				
FY 2026 (Forecast)		80.00	—	80.00	160.00

(Note) Revisions to the latest dividend forecast: No

3. Consolidated Financial Forecast for Fiscal 2026 (April 1, 2026 – March 31, 2027)

(Percentage figures show year on year change)

	Revenue		Operating profit		Profit before income taxes		Profit for the year		Profit for the year attributable to owners of the parent		Earnings per share attributable to owners of the parent (basic)
	(¥ million)	(%)	(¥ million)	(%)	(¥ million)	(%)	(¥ million)	(%)	(¥ million)	(%)	(¥)
Fiscal Year	883,500	7.0	70,000	58.6	74,000	45.1	54,000	33.3	52,300	35.6	185.00

(Note) Revisions to the latest financial forecast: No

* Explanatory Notes

(1) Changes in number of significant subsidiaries during the period (changes in specified subsidiaries resulting in a change in scope of consolidation): No

(2) Changes in accounting policies and accounting estimates:
1) Changes in accounting policies required by IFRS: Yes
2) Changes in accounting policies other than 1): No
3) Changes in accounting estimates: No

(3) Number of shares issued (common shares):

1) Number of shares issued (including treasury shares)	As of June 30, 2026	291,649,149	As of March 31, 2026	291,649,149
2) Number of treasury shares	As of June 30, 2026	9,190,146	As of March 31, 2026	9,535,293
3) Weighted average number of shares outstanding	For the three-month period ended June 30, 2026	281,890,450	For the three-month period ended June 30, 2025	281,887,947

The Company's shares held through a trust (568,840 shares) are not included in the number of treasury shares as of the end of the period, but are included in the average number of shares outstanding as treasury shares that are deducted from the calculation of earnings per share.

* Review of attached Interim Consolidated Financial Statements by independent auditors: No

* Explanation concerning the appropriate use of results forecast and other special instructions:

(Caution concerning forward-looking statements)
Materials and information provided in this financial disclosure may contain "forward-looking statements" based on expectations, business goals, estimates, forecasts and assumptions that are subject to risks and uncertainties as of the publication date of these materials. Accordingly, actual outcomes and results may differ materially from these statements depending on a number of important factors. Please refer to page 7 for details with regard to the assumptions and other related matters concerning the consolidated financial forecast.

(Methods for obtaining supplementary materials and content of financial results disclosure meeting)
Supplementary materials are attached to this financial report. The Company plans to hold a financial results disclosure meeting for institutional investors and securities analysts on Monday, August 3, 2026. The handouts for the disclosure meeting will be made available on the Company's website.

Supplemental Materials: Table of Contents

1. Qualitative Information regarding Financial Results for the Period

(1) Operating Results

[Revenue and Profit]

○ Eisai Co., Ltd. (“the Company”) and its affiliates (collectively referred to as “the Group”) recorded the following consolidated financial results for the three-month period ended June 30, 2026.

(¥billion)

	Three-month period ended June 30, 2025	**Three-month period ended June 30, 2026**	% Change
Revenue	202.7	**234.3**	+15.6%
Cost of sales	42.6	**51.1**	+19.9%
Gross profit	160.1	**183.2**	+14.5%
Selling, general and administrative expenses	100.2	**114.8**	+14.6%
Research and development expenses	38.8	**43.7**	+12.7%
Operating profit	20.7	**24.7**	+19.2%
Profit before income taxes	22.4	**25.3**	+12.8%
Profit for the period	15.3	**19.2**	+24.9%
Profit for the period attributable to owners of the parent	14.5	**18.2**	+26.0%
(Reference) Core operating profit	21.7	**24.7**	+13.9%

(Core Operating Profit: an indicator of fundamental earning calculated by excluding temporary income and expenses from operating profit; see page 2 of the Reference Data for details of the adjustments.)

○ Revenue significantly increased due to continued growth of anticancer agent Lenvima, Alzheimer’s disease (AD) treatment Leqembi, and insomnia treatment Dayvigo, in addition to the depreciation of the Japanese yen. Revenue of pharmaceutical business came to ¥230.9 billion (up 16.4% year on year).

○ Regarding revenue from major products, revenue for Lenvima, Leqembi, and Dayvigo all achieved significant growth, coming to ¥97.3 billion (up 15.9% year on year), ¥29.3 billion (up 26.7% year on year), and ¥18.9 billion (up 37.9% year on year), respectively.

○ Selling, general and administrative expenses increased due to shared profit paid to Merck & Co., Inc., Rahway, NJ, USA following Lenvima’s revenue growth and proactive resource investment for Leqembi.

○ Research and development expenses increased due to continuous proactive resource investment in important projects such as Leqembi, anti-microtubule binding region (MTBR) tau antibody E2814, and novel selective orexin 2 receptor agonist E2086.

○ Operating profit significantly increased due to growth of major products, absorbing the impact of stockpiling by distributors in China in the same period of the previous fiscal year. Core operating profit, which indicates fundamental earning, came to ¥24.7 billion (up 13.9% year on year).

[Performance by Segment]

(Revenue for each segment indicates revenue from external customers)

The Group's business is comprised of pharmaceutical business and other business. The pharmaceutical business is organized into the following five reporting segments in this report: Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia and Oceania), and East Asia Global South (primarily South Korea, Taiwan, India, ASEAN, Central and South America, and South Africa).

<Japan pharmaceutical business>

○ Total revenue came to ¥57.9 billion (up 3.4% year on year), with a segment profit of ¥21.0 billion (up 8.1% year on year). Breakdown of revenue was ¥52.7 billion (up 4.1% year on year) from prescription medicines and ¥5.2 billion (down 3.5% year on year) from OTC and others.

○ Regarding revenue by product, revenue for Dayvigo and Leqembi achieved significant growth coming to ¥12.4 billion (up 13.4% year on year) and ¥6.1 billion (up 10.9% year on year), respectively. Revenue for Lenvima achieved growth coming to ¥3.7 billion (up 3.0% year on year). Revenue for JAK (Janus kinase) inhibitor Jyseleca, chronic constipation treatment MOVICOL and chronic constipation treatment Goofice achieved significant growth coming to ¥5.4 billion (up 25.2% year on year), ¥3.0 billion (up 48.3% year on year) and ¥2.6 billion (up 18.2% year on year), respectively. Revenue for antiepileptic agent Fycompa achieved growth coming to ¥2.2 billion (up 5.8% year on year). In OTC and others, revenue for Chocola BB Group achieved growth coming to ¥3.9 billion (up 1.1% year on year).

<Americas pharmaceutical business>

○ Total revenue came to ¥86.6 billion (up 22.3% year on year), with a segment profit of ¥51.9 billion (up 25.0% year on year).

○ Regarding revenue by product, revenue for Lenvima, Leqembi and Dayvigo achieved significant growth coming to ¥66.5 billion (up 14.5% year on year), ¥15.5 billion (up 70.5% year on year) and ¥3.3 billion (up 74.5% year on year), respectively.

<China pharmaceutical business>

○ Total revenue came to ¥42.5 billion (up 16.6% year on year), with a segment profit of ¥21.2 billion (up 18.2% year on year).

○ Regarding revenue by product, revenue for Lenvima came to ¥6.8 billion (down 0.9% year on year). Revenue for Leqembi came to ¥4.8 billion (down 37.3% year on year), due to the impact of stockpiling by distributors in the same period of the previous fiscal year. Revenue for Dayvigo came to ¥1.4 billion (¥0.1 billion in the same period of the previous fiscal year). Revenue for vertigo and equilibrium disturbance treatment Merislon and peripheral neuropathy treatment Methycobal achieved significant growth coming to ¥5.1 billion (up 67.1% year on year), and ¥3.7 billion (up 27.7% year on year), respectively.

<EMEA pharmaceutical business>

○ Total revenue came to ¥23.6 billion (up 24.4% year on year), with a segment profit of ¥12.5 billion (up 51.8% year on year).

○ Regarding revenue by product, revenue for Lenvima/Kisplyx, Leqembi and Fycompa all achieved significant growth coming to ¥15.1 billion (up 36.6% year on year), ¥0.5 billion (up 341.2% year on year), and ¥4.8 billion (up 18.3% year on year), respectively.

○ Leqembi was launched in Belgium and Australia in June 2026.

<East Asia Global South pharmaceutical business>

○ Total revenue came to ¥20.2 billion (up 25.3% year on year), with a segment profit of ¥9.5 billion (up 15.0% year on year).

○ Regarding revenue by product, revenue for Lenvima and Leqembi achieved significant growth coming to ¥5.2 billion (up 20.3% year on year) and ¥2.4 billion (up 214.0% year on year), respectively. Revenue for Alzheimer's disease treatment Aricept came to ¥3.6 billion (down 4.0% year on year).

○ Leqembi was launched in Brazil and India in June 2026.

(2) Financial Position

[Assets, Liabilities, and Equity]

○ Total assets as of the end of the period amounted to ¥1,558.1 billion (up ¥109.0 billion from the end of the previous fiscal year). Inventories increased due to proceeding the production of Leqembi and others, in addition to an increase in trade and other receivables mainly due to an increase in revenue.

○ Total liabilities as of the end of the period amounted to ¥624.9 billion (up ¥100.9 billion from the end of the previous fiscal year). Bonds and borrowings increased due to unsecured straight bond issuance and others.

○ Total equity as of the end of the period amounted to ¥933.2 billion (up ¥8.0 billion from the end of the previous fiscal year). Exchange differences on translation of foreign operations increased due to impact of the exchange rate.

○ As a result of the above, the ratio of equity attributable to owners of the parent was 58.2% (down 3.9 percentage points from the end of the previous fiscal year).

[Cash Flows]

○ Net cash from operating activities amounted to an outflow of ¥2.6 billion (inflow of ¥1.1 billion in the same period of previous fiscal year). Working capital increased due to an increase in accounts receivable and inventories for Leqembi and others.

○ Net cash used in investing activities amounted to an inflow of ¥6.5 billion (outflow of ¥9.4 billion in the same period of previous fiscal year), mainly due to proceeds from the sale of financial assets.

○ Net cash from financing activities amounted to an inflow of ¥57.9 billion (up ¥31.8 billion from the same period of previous fiscal year). While dividends were paid, inflow from bonds and short-term borrowings increased.

○ As a result of the above, cash and cash equivalents as of the end of the period stood at

¥311.7 billion (up ¥66.3 billion from the end of the previous fiscal year). Free cash flow (cash flow from operating activities excluding capital expenditures) for the year was an inflow of ¥4.0 billion.

(3) Research & Development Pipeline, Alliances, and Other Events

[Status of Ongoing Research & Development Pipelines]

○ Anticancer agent Lenvima (lenvatinib, jointly developed with Merck & Co., Inc., Rahway, NJ, USA)

- Approved as a monotherapy for use in the treatment of thyroid cancer and hepatocellular carcinoma (first-line) mainly in Japan, the United States, Europe, China and Asia.
- Approved as a monotherapy for use in the treatment of unresectable thymic carcinoma in Japan and Asia.
- Approved in combination with everolimus for use in the treatment of renal cell carcinoma (second-line) mainly in the United States, Europe and Asia.
- Approved in combination with pembrolizumab, Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, for use in the treatment of renal cell carcinoma (first-line) and endometrial carcinoma (following prior systemic therapy) mainly in Japan, the United States, Europe and Asia.
- Approved in combination with pembrolizumab and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma in China.
- Regarding a combination treatment with Merck & Co., Inc., Rahway, NJ, USA's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan, applications have been submitted seeking approval for advanced renal cell carcinoma in Japan and the United States, and the Prescription Drug User Fee Act (PDUFA) action date in the United States is set for October 4, 2026.
- In April 2026, regarding the triplet therapy with Merck & Co., Inc., Rahway, NJ, USA's pembrolizumab and belzutifan, at a pre-specified interim analysis of the Phase III clinical study conducted by Merck & Co., Inc., Rahway, NJ, USA for advanced renal cell carcinoma (first-line), the triplet regimen did not meet the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to pembrolizumab plus Lenvima.

○ AD treatment Leqembi (lecanemab, jointly developed with Biogen Inc. (U.S.))

- Approved as a treatment for early AD in 53 countries and regions including Japan, the United States, China, Europe, and Asia, with applications submitted in 6 countries.
- Approved for once every four weeks intravenous maintenance treatment after an 18-month initiation phase with once every two weeks treatment in 8 countries including the United States and China, with applications submitted in 12 countries and regions including Europe (EU).
- Approved as a subcutaneous autoinjector (SC-AI) for maintenance treatment (360mg, once weekly) in the United States.
- In July 2026, initiation treatment by SC-AI (500mg, once weekly) was approved in the United States, with applications submitted in 4 countries including Japan and China. In China, the application has been granted priority review designation.

- AHEAD 3-45 (Phase III study) for preclinical (asymptomatic) AD is underway in partnership with the Alzheimer's Clinical Trials Consortium (ACTC) in countries including Japan, the United States and Europe.

○ Insomnia treatment Dayvigo (lemborexant)
- Approved for the treatment of insomnia mainly in Japan, the United States, China and Asia.
- In June 2026, a Marketing Authorisation Application was accepted in the United Kingdom for the treatment of adult patients with insomnia, characterized by symptoms present for at least 3 months with considerable impact on daytime functioning.
- In July 2026, a Marketing Authorisation Application was accepted in Europe (EU) for the treatment of adult patients with chronic insomnia.

○ Regarding anticancer agent taletrectinib, a Marketing Authorisation Application for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) was accepted in the United Kingdom in June 2026.

[Major Alliances and Agreements]

○ In June 2026, Eisai entered into a partnership with Mitsubishi UFJ Trust and Banking Corporation (Tokyo) to provide information on cognitive function as part of initiatives aimed at dementia prevention.

○ In June 2026, Eisai announced that it has signed an agreement with University College London to extend the partnership on drug discovery and development research for neurodegenerative diseases until 2030.

○ In July 2026, Eisai announced that it will commence the co-promotion of Nurtec OD Tablet 75mg (rimegepant), manufactured and marketed by Pfizer Japan Inc. (Tokyo), for acute treatment and prophylaxis of migraine in Japan from September 2026.

[Other Events]

○ In May 2026, Eisai was selected for the highest rating of Supplier Engagement Leader in the Supplier Engagement Rating by the non-profit organization CDP (the United Kingdom). This is the second consecutive year that Eisai has been selected.

○ In June 2026, Eisai issued ¥50.0 billion of unsecured straight bonds to diversify its financing sources for growth investments.

○ In June 2026, Eisai announced a strategic investment supported by the United Kingdom Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.

(4) Information on Outlook for the Future including Financial Forecast (April 1, 2026 – March 31, 2027)

[Consolidated Financial Forecast]

○ There are no changes to the consolidated financial forecast announced on May 15, 2026.

	FY2025	**FY2026 Forecast**	% Change
Revenue	¥825.4 billion	**¥883.5 billion**	+7.0%
Operating profit	¥44.1 billion	**¥70.0 billion**	+58.6%
Profit before income taxes	¥51.0 billion	**¥74.0 billion**	+45.1%
Profit for the year	¥40.5 billion	**¥54.0 billion**	+33.3%
Profit for the year attributable to owners of the parent	¥38.6 billion	**¥52.3 billion**	+35.6%
Earnings per share attributable to owners of the parent (basic)	¥136.78	**¥185.00**	+35.3%

Core operating profit	¥50.1 billion	**¥70.0 billion**	+39.8%

(Assumptions: 1 USD = ¥153.0, 1 EUR = ¥180.0, 1 GBP = ¥205.0, 1 RMB = ¥22.5)

[Forecasts and Risk Factors]

The materials and information provided in this announcement include current forecasts, targets, evaluations, estimates, assumptions that are accompanied by risks, and other matters that are based on uncertain factors. Accordingly, it is possible that actual results will deviate significantly from forecasts, etc., due to changes to a variety of factors. These risks and uncertainties include general industry and market conditions, changes in tariff policies in various countries, fluctuation of interest rates and currency exchange rates, and other aspects of economic conditions in Japan and internationally.

For further details on risks and uncertainties that could cause significant fluctuations in the results of the Group or have a material effect on investment decisions, please refer to the “Risk Factors” section of the Annual Securities Report in the previous fiscal year. However, these do not cover all of the risks and uncertainties faced by the Group, and it is possible that they will be affected in the future by other factors that cannot be foreseen, or are not deemed to be important, at this point in time.

These are judgments as of the time of the announcement, and statements in the text regarding the future are not guarantees that they will occur or be achieved.

2. Condensed Interim Consolidated Financial Statements and Major Notes

(1) Condensed Interim Consolidated Statement of Income

(Millions of yen)

	Three-month period ended June 30, 2026	Three-month period ended June 30, 2025
Revenue	234,330	202,651
Cost of sales	(51,089)	(42,600)
Gross profit	183,241	160,051
Selling, general and administrative expenses	(114,827)	(100,164)
Research and development expenses	(43,713)	(38,792)
Other income	507	262
Other expenses	(479)	(615)
Operating profit	24,728	20,744
Financial income	2,512	2,577
Financial costs	(1,956)	(916)
Profit before income taxes	25,283	22,404
Income taxes	(6,132)	(7,068)
Profit for the period	19,151	15,337
Profit for the period attributable to		
Owners of the parent	18,242	14,474
Non-controlling interests	909	862
Earnings per share		
Basic (yen)	64.71	51.35
Diluted (yen)	—	—

(2) Condensed Interim Consolidated Statement of Comprehensive Income

(Millions of yen)

	Three-month period ended June 30, 2026	Three-month period ended June 30, 2025
Profit for the period	19,151	15,337
Other comprehensive income (loss)		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income (loss)	(2,331)	3,036
Subtotal	(2,331)	3,036
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	14,381	(7,293)
Cash flow hedges	(24)	(12)
Subtotal	14,356	(7,305)
Total other comprehensive income (loss), net of tax	12,025	(4,270)
Comprehensive income (loss) for the period	31,177	11,067
Comprehensive income (loss) for the period attributable to		
Owners of the parent	30,262	10,214
Non-controlling interests	915	853

(3) Condensed Interim Consolidated Statement of Financial Position

(Millions of yen)

	As of June 30, 2026	As of March 31, 2026
Assets		
Non-current assets		
Property, plant and equipment	159,726	161,042
Goodwill	263,151	259,200
Intangible assets	85,624	88,125
Other financial assets	50,207	62,412
Other assets	8,609	8,658
Deferred tax assets	107,760	108,039
Total non-current assets	675,078	687,477
Current assets		
Inventories	282,008	257,547
Trade and other receivables	253,125	227,002
Other financial assets	1,576	892
Other assets	34,565	30,773
Cash and cash equivalents	311,739	245,423
Total current assets	883,013	761,637
Total assets	1,558,091	1,449,113

(Millions of yen)

	As of June 30, 2026	As of March 31, 2026
Equity		
Equity attributable to owners of the parent		
Share capital	44,986	44,986
Capital surplus	74,188	74,307
Treasury shares	(42,290)	(42,288)
Retained earnings	504,261	510,919
Other components of equity	325,419	311,068
Total equity attributable to owners of the parent	906,564	898,992
Non-controlling interests	26,606	26,131
Total equity	933,169	925,124
Liabilities		
Non-current liabilities		
Bonds and Borrowings	184,604	134,777
Other financial liabilities	33,595	33,806
Provisions	1,579	1,584
Other liabilities	9,527	11,887
Deferred tax liabilities	1,974	1,682
Total non-current liabilities	231,279	183,736
Current liabilities		
Bonds and Borrowings	86,738	51,304
Trade and other payables	87,531	75,892
Other financial liabilities	22,106	16,264
Income taxes payable	6,212	6,672
Provisions	51,877	46,632
Other liabilities	139,178	143,489
Total current liabilities	393,642	340,254
Total liabilities	624,922	523,990
Total equity and liabilities	1,558,091	1,449,113

(4) Condensed Interim Consolidated Statement of Changes in Equity

For the three-month period ended June 30, 2026

(Millions of yen)

	Equity attributable to owners of the parent				
					Other components of equity
	Share capital	Capital surplus	Treasury shares	Retained earnings	Financial assets measured at fair value through other comprehensive income (loss)
As of April 1, 2026	44,986	74,307	(42,288)	510,919	—
Profit for the period	—	—	—	18,242	—
Total other comprehensive income (loss)	—	—	—	—	(2,331)
Comprehensive income (loss) for the period	—	—	—	18,242	(2,331)
Dividends	—	—	—	(22,569)	—
Acquisition of treasury shares	—	—	(2)	—	—
Changes in ownership interest in subsidiaries	—	(119)	—	—	—
Reclassification	—	—	—	(2,331)	2,331
Total transactions with owners	—	(119)	(2)	(24,900)	2,331
As of June 30, 2026	44,986	74,188	(42,290)	504,261	—

	Equity attributable to owners of the parent					
	Other components of equity					
	Exchange differences on translation of foreign operations	Cash flow hedges	Total other components of equity	Total equity attributable to owners of the parent	Non-controlling interests	Total equity
As of April 1, 2026	311,029	40	311,068	898,992	26,131	925,124
Profit for the period	—	—	—	18,242	909	19,151
Total other comprehensive income (loss)	14,375	(24)	12,020	12,020	6	12,025
Comprehensive income (loss) for the period	14,375	(24)	12,020	30,262	915	31,177
Dividends	—	—	—	(22,569)	(560)	(23,129)
Acquisition of treasury shares	—	—	—	(2)	—	(2)
Changes in ownership interest in subsidiaries	—	—	—	(119)	119	—
Reclassification	—	—	2,331	—	—	—
Total transactions with owners	—	—	2,331	(22,690)	(440)	(23,131)
As of June 30, 2026	325,404	15	325,419	906,564	26,606	933,169

For the three-month period ended June 30, 2025

(Millions of yen)

	Equity attributable to owners of the parent				
					Other components of equity
	Share capital	Capital surplus	Treasury shares	Retained earnings	Financial assets measured at fair value through other comprehensive income (loss)
As of April 1, 2025	44,986	74,843	(42,294)	511,917	—
Profit for the period	—	—	—	14,474	—
Total other comprehensive income (loss)	—	—	—	—	3,036
Comprehensive income (loss) for the period	—	—	—	14,474	3,036
Dividends	—	—	—	(22,569)	—
Acquisition of treasury shares	—	—	(3)	—	—
Disposal of treasury shares	—	(0)	0	—	—
Acquisition of subsidiaries	—	—	—	—	—
Changes in ownership interest in subsidiaries	—	(552)	—	—	—
Reclassification	—	—	—	3,036	(3,036)
Total transactions with owners	—	(552)	(3)	(19,534)	(3,036)
As of June 30, 2025	44,986	74,291	(42,297)	506,858	—

	Equity attributable to owners of the parent					
	Other components of equity					
	Exchange differences on translation of foreign operations	Cash flow hedges	Total other components of equity	Total equity attributable to owners of the parent	Non-controlling interests	Total equity
As of April 1, 2025	251,796	169	251,965	841,417	24,551	865,968
Profit for the period	—	—	—	14,474	862	15,337
Total other comprehensive income (loss)	(7,283)	(12)	(4,260)	(4,260)	(10)	(4,270)
Comprehensive income (loss) for the period	(7,283)	(12)	(4,260)	10,214	853	11,067
Dividends	—	—	—	(22,569)	(513)	(23,083)
Acquisition of treasury shares	—	—	—	(3)	—	(3)
Disposal of treasury shares	—	—	—	0	—	0
Acquisition of subsidiaries	—	—	—	—	179	179
Changes in ownership interest in subsidiaries	—	—	—	(552)	(44)	(596)
Reclassification	—	—	(3,036)	—	—	—
Total transactions with owners	—	—	(3,036)	(23,124)	(379)	(23,503)
As of June 30, 2025	244,512	157	244,669	828,507	25,025	853,532

(5) Condensed Interim Consolidated Statement of Cash Flows

(Millions of yen)

	For the three-month period ended June 30, 2026	For the three-month period ended June 30, 2025
Operating activities		
Profit before income taxes	25,283	22,404
Depreciation and amortization	9,420	9,697
Impairment losses	—	1,309
(Increase) decrease in working capital	(29,725)	(25,972)
Interest and dividends received	1,965	2,102
Interest paid	(1,214)	(879)
Income taxes paid	(6,741)	(4,331)
Other	(1,575)	(3,236)
Net cash from (used in) operating activities	(2,588)	1,094
Investing activities		
Purchases of property, plant and equipment	(4,259)	(4,534)
Purchases of intangible assets	(963)	(2,597)
Proceeds from sale of property, plant and equipment and intangible assets	1,906	113
Net cash outflow on acquisition of subsidiaries	—	(12,584)
Purchases of financial assets	(974)	(196)
Proceeds from sale and redemption of financial assets	10,909	10,473
Payments of time deposits exceeding three months	—	(1)
Proceeds from redemption of time deposits exceeding three months	—	0
Other	(161)	(44)
Net cash from (used in) investing activities	6,457	(9,369)
Financing activities		
Net increase (decrease) in short-term borrowings	34,010	51,677
Proceeds from issuance of bonds and long-term borrowings	50,000	—
Redemption of bonds and repayments of long-term borrowings	(2)	(2)
Repayments of lease liabilities	(2,764)	(2,585)
Dividends paid	(22,569)	(22,569)
Other	(750)	(425)
Net cash from (used in) financing activities	57,925	26,095
Effect of exchange rate change on cash and cash equivalents	4,522	2,000
Net increase (decrease) in cash and cash equivalents	66,316	19,819
Cash and cash equivalents at beginning of period	245,423	265,561
Cash and cash equivalents at end of period	311,739	285,380

(6) Notes to Condensed Interim Consolidated Financial Statements

(Going Concern)

Not applicable

(Changes in Accounting Policies)

With the exception of the following, all material accounting policies that are applied to these condensed interim consolidated financial statements for this period are the same as those that were applied to the consolidated financial statements for the previous fiscal year. None of the following accounting standards and interpretations applied by the Group has any major impact on the condensed interim consolidated financial statements for this period.

Accounting standards and interpretations	Mandatory application (Date of commencement)	To be applied by the Group	Description
IFRS 7 Financial Instruments: Disclosures IFRS 9 Financial Instruments	January 1, 2026	Fiscal year ending March 31, 2027	• Clarification of accounting and disclosures related to contracts referencing nature-dependent electricity • Clarification of the classification of financial assets containing ESG-linked and similar features

(Segment Information)

Reporting segments are units for which the Group can obtain independent financial information and for which top management undertakes periodic reviews in order to determine the allocation of management resources and evaluate performance.

The Group's business is comprised of pharmaceutical business and other business. The pharmaceutical business is organized into the following five reporting segments in this report: Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia and Oceania), and East Asia Global South (primarily South Korea, Taiwan, India, ASEAN, Central and South America, and South Africa).

(Millions of yen)

	Three-month period ended June 30, 2026		Three-month period ended June 30, 2025	
	Revenue	Segment profit (loss)	Revenue	Segment profit (loss)
Pharmaceutical business				
Japan	57,940	21,032	56,048	19,448
Americas	86,576	51,936	70,801	41,540
China	42,527	21,178	36,461	17,917
EMEA	23,646	12,451	19,007	8,200
East Asia Global South	20,212	9,481	16,130	8,241
Reporting segment total	230,901	116,079	198,448	95,347
Other business (Note 1)	3,429	1,251	4,203	2,234
Total	234,330	117,330	202,651	97,581
R&D expenses (Note 2)	—	(38,883)	—	(34,239)
Group headquarters' management costs and other expenses (Note 3)	—	(53,719)	—	(42,598)
Operating profit in the condensed interim consolidated statement of income	—	24,728	—	20,744

(Note 1) "Other business" mainly includes the license revenue and pharmaceutical ingredient business of the parent company.

(Note 2) "R&D expenses" do not include expenses associated with medical activities, which are reflected in each reporting segment.

(Note 3) "Group headquarters' management costs and other expenses" are the costs and expenses covering Group-wide operations which include the amount of other income and expenses, and the amount of profits and expenses shared under strategic collaborations with partners. For the three-month period ended June 30, 2026, shared profit of ¥44,252 million (¥36,022 million for the three-month period ended June 30, 2025) for anticancer agent Lenvima paid by the Group to Merck & Co., Inc., Rahway, NJ, USA was included in Group headquarters' management costs and other expenses.

(Consolidated Statement of Income)

(1) Selling, general and administrative expenses (SG&A expenses)

For the three-month period ended June 30, 2026, the Group recognized shared profit of ¥44,252 million (¥36,022 million for the three-month period ended June 30, 2025) for anticancer agent Lenvima paid by the Group to Merck & Co., Inc., Rahway, NJ, USA as SG&A expenses.

(Consolidated Statement of Cash Flows)

(1) Net cash outflow on acquisition of subsidiaries

For the three-month period ended June 30, 2025, net cash outflow on acquisition of subsidiaries of ¥12,584 million was due to the acquisition of shares of EcoNaviSta, Inc.

(Significant Subsequent Events)

Not applicable